Compare predictions BIIB vs BMY
Loading...
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongSell and BMY is a StrongSell.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 0 FA rating(s) are green whileBMY’s FA Score has 1 green FA rating(s).
- BIIB’s FA Score: 0 green, 5 red.
- BMY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish.
- BMY’s TA Score: 4 bullish, 4 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +0.54% price change this week, while BMY (@Pharmaceuticals: Major) price change was -0.15% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.75%. For the same industry, the average monthly price growth was -4.10%, and the average quarterly price growth was -2.82%.
Reported Earning Dates
BIIB is expected to report earnings on Oct 24, 2023.
BMY is expected to report earnings on Oct 26, 2023.
Industries' Descriptions
@Pharmaceuticals: Major (-2.75% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BIIB | BMY | BIIB / BMY | |
| Capitalization | 36.9B | 124B | 30% |
| EBITDA | 3.82B | 19.8B | 19% |
| Gain YTD | -6.814 | -16.585 | 41% |
| P/E Ratio | 13.91 | 15.72 | 88% |
| Revenue | 9.97B | 45.2B | 22% |
| Total Cash | 6.08B | 8.73B | 70% |
| Total Debt | 6.59B | 39.2B | 17% |
BIIB | BMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 55 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 58 | |
SMR RATING 1..100 | 47 | 39 | |
PRICE GROWTH RATING 1..100 | 56 | 61 | |
P/E GROWTH RATING 1..100 | 62 | 85 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (4) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (93) in the Biotechnology industry. This means that BMY’s stock grew significantly faster than BIIB’s over the last 12 months.
BMY's Profit vs Risk Rating (58) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (100) in the Biotechnology industry. This means that BMY’s stock grew somewhat faster than BIIB’s over the last 12 months.
BMY's SMR Rating (39) in the Pharmaceuticals Major industry is in the same range as BIIB (47) in the Biotechnology industry. This means that BMY’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's Price Growth Rating (56) in the Biotechnology industry is in the same range as BMY (61) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to BMY’s over the last 12 months.
BIIB's P/E Growth Rating (62) in the Biotechnology industry is in the same range as BMY (85) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to BMY’s over the last 12 months.
| BMY | |
|---|---|
| RSI ODDS (%) | 1 day ago 75% |
| Stochastic ODDS (%) | 1 day ago 53% |
| Momentum ODDS (%) | 1 day ago 52% |
| MACD ODDS (%) | 1 day ago 54% |
| TrendWeek ODDS (%) | 1 day ago 51% |
| TrendMonth ODDS (%) | 1 day ago 49% |
| Advances ODDS (%) | 7 days ago 57% |
| Declines ODDS (%) | 10 days ago 54% |
| BollingerBands ODDS (%) | 1 day ago 62% |
| Aroon ODDS (%) | N/A |
BIIB and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AZN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AZN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | +1.19% | ||
| AZN - BIIB | 34% Loosely correlated | -1.04% | ||
| JNJ - BIIB | 32% Poorly correlated | -0.77% | ||
| MRK - BIIB | 29% Poorly correlated | -0.43% | ||
| PFE - BIIB | 29% Poorly correlated | -1.76% | ||
| ABBV - BIIB | 27% Poorly correlated | -0.48% | ||
More | ||||